期刊
JOURNAL OF NUCLEAR MEDICINE
卷 56, 期 3, 页码 436-443出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.114.145011
关键词
Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone) PET; 16 alpha-F-18-fluoro-17 beta-estradiol PET; diffusion weighted imaging; dynamic contrast enhanced MRI; perfusion MRI
MR imaging and F-18-FDG PET/CT play central and complementary roles in the care of patients with gynecologic cancer. Because treatment often requires combinations of surgery, radiotherapy, and chemotherapy, imaging is central to triage and to determining prognosis. This article reviews the use of the 2 imaging modalities in the initial evaluation of 3 common cancers: uterine cervical, uterine endometrial, and epithelial ovarian. Imaging features that affect management are highlighted, as well as the relative strengths and weaknesses of the 2 modalities. Use of imaging after initial therapy to assess for recurrence and to plan salvage therapy is described. Newer functional and molecular techniques in MR imaging and PET are evaluated. Finally, we describe our initial experience with PET/MR imaging, an emerging technology that may prove to be a mainstay in personalized gynecologic cancer care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据